• Explore /
  • Poster
  • / CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.

CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.

Abstract Poster

Authors

null

Nizar M. Tannir

The University of Texas MD Anderson Cancer Center, Houston, TX

Nizar M. Tannir , Neeraj Agarwal , Nancy Ann Dawson , Robert J. Motzer , Carmel Maree Jacobs , Toni K. Choueiri , John Stewart Hrom , Daniel M. Geynisman , Nancy B. Davis , Robert A. Figlin , Mary Kathleen O'Keeffe , Jigarkumar R. Parikh , Daniel A. Vaena , Ping-Yu Liu , Bridget O'Keeffe , Xuan Tran , Bernard Escudier

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT03428217

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr TPS682)

DOI

10.1200/JCO.2019.37.7_suppl.TPS682

Abstract #

TPS682

Poster Bd #

K13

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: Funda Meric-Bernstam

First Author: Hai-Qiang Mai

First Author: Wei Wang